Skip to content
etf.net

Launched · SEC filings

ARK Genomic Revolution ETF

ARKGCboeD

$48.51−0.97 (−1.96%)

At close: Oct 13, 2026, 4:00 PM

D34/ 100

Rank 15 of 17 in Biotech & Genomics

D34/100Rank 15 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 49.48 to 48.51. Range 48.31 to 49.06. Use the arrow keys to read each point.48.2548.7549.0049.2510 AM12 PM2 PM4 PM
Expense ratio
0.75%
Fund size
$2.2B
1Y total return
+63.0%
Yield · Last 12 months
0.00%
Holdings
34
Avg volume · 30D
4M sh
NAV per share
$51.32
52W range
low $24.60high $58.83
Launched
Filings
SEC EDGAR

The ETF.net ARKG Grade

D

Score 34 out of 100

Category
Biotech & Genomics⁠
Rank
15 of 17
Six-pillar profile for ARKG. Scores out of 100: Cost 6, Risk 13, Mission 45, Tradability 83, Holdings 32, Durability 73. Strongest: Tradability (83). Weakest: Cost (6). Leans toward Tradability.

Score 34 of 100 falls in the D band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F6 out of 100
    Rank 16 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    C45 out of 100
    Rank 9 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    F13 out of 100
    Rank 17 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    A83 out of 100
    Rank 3 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    D32 out of 100
    Rank 16 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    A73 out of 100
    Rank 5 of 17

Our read on ARKG

ETF.net Research

DMost genomics exposure comes prepackaged in an index. ARKG is the active version: ARK's team hand-picks a global slate of companies tied to the genomics revolution, and has since 2014.

Stated mandate

The Fund seeks long-term growth of capital through active investment, primarily in domestic and foreign equity securities of companies relevant to the genomics revolution theme.

Why people hold it

  1. 01Active by design. ARK's managers choose the names instead of tracking a genomics index, so the portfolio can move as the science does.
  2. 02Global mandate. The prospectus puts both domestic and foreign equities in bounds, so the hunt for genomics names isn't fenced in at the US border.
  3. 03Live since 2014 and now a multibillion-dollar fund that trades actively, which makes getting in and out one of the easier parts of owning it.

Worth knowing

  1. 01The stock picking costs you: 0.75% a year, above the category median, while index rivals like IBB (0.44%) and XBI (0.35%) charge less for broad biotech.
  2. 02It sits at the more volatile end of its peer group. Concentrated bets on young science companies swing hard in both directions.
  3. 03Long-term growth of capital is the stated job. Income isn't part of the mandate, so there's no dividend cushioning the ride.

ARKG Holdings

As of Oct 12, 2026
Asset class
Stocks
Holdings
34
Top-10 weight
58%
Largest holding
TXG9.3%

Sectors

  • Health Care97.1%
  • Technology2.9%

Geography

  • United States91.91%
  • Switzerland5.47%
  • United Kingdom2.63%
The fund’s holdings, weight-ordered — page 1 of 3.
#TickerCompanyWeight %SharesMarket valueIn ETFs
001TXG10X Genomics Inc-Class A9.26%2,446,807$197M137
002TWSTTwist Bioscience Corp8.65%1,153,143$184M125
003TEMTempus Ai Inc-Cl A8.18%2,456,823$174M107
004CRSPCrispr Therapeutics AG5.40%2,155,459$115M81
005ABSIAbsci Corp5.05%10,581,097$108M67
006ILMNIllumina Inc4.83%370,036$103M322
007NTRANatera Inc4.65%246,976$99M238
008GHGuardant Health Inc4.64%589,795$99M175
009CDNACaredx Inc3.91%1,306,490$83M111
010PSNLPersonalis Inc3.72%4,951,655$79M62
011LLYEli Lilly & Co3.62%65,296$77M583
012VCYTVeracyte Inc3.30%1,553,681$70M140
013BEAMBeam Therapeutics Inc3.28%2,716,466$70M93
014RXRXRecursion Pharmaceuticals-A3.01%14,727,265$64M86
015SDGRSchrodinger Inc2.88%2,245,494$61M86

Showing 1–15 of 34 holdings

ARKG Performance

Launched Oct 31, 2014

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

ARKG$16,303
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$12,044
Oct 10, 2025 to Oct 12, 2026. ARKG $16,303. SPY $12,044. Use the arrow keys to read each point.$7,403$13,473$19,542Oct 2025Apr 2026Oct 2026

Oct 10, 2025 – Oct 12, 2026

Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for ARKG. Periods over one year show the average yearly return.
PeriodARKG
Year to date+70.8%
1 month+8.6%
3 months+19.7%
1 year+63.0%
3 yearsper year+25.5%
5 yearsper year−7.3%
10 yearsper year+11.5%

As of the close, with distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for ARKG
YearReturn barARKG
2026 YTD+70.8%
2025+23.0%
2024−28.2%
2023+16.2%
2022−53.9%
2021−33.9%
2020+180.6%

ARKG in the news

ARKG Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 12, 2026.
0.00%Last 12 months
Payout per share
NoneLast 12 months

No distributions in the last 12 months.

Distribution history

Payments through 2021

One bar per payment. 5 payments from 2017 to 2021. Dec 27, 2017 $0.33; Dec 27, 2018 $0.47; Dec 27, 2019 $1.05; Dec 29, 2020 $0.79; Dec 29, 2021 $0.38. Use the arrow keys to read each point.20172018201920202021
Ex-datePay dateAmount per share
Dec 29, 2021Dec 31, 2021$0.38
Dec 29, 2020Dec 31, 2020$0.79
Dec 27, 2019Dec 31, 2019$1.05
Dec 27, 2018Dec 31, 2018$0.47
Dec 27, 2017Dec 29, 2017$0.33

ARKG Risk

How much the fund’s monthly returns vary, scaled to a year.
42.3%
Annualised · 36 months to Sep 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
0.63
vs 3-month T-bills · to Sep 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−76.5%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
2.38
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

ARKG Cost

Expense ratio0.75%
  • The middle half of Biotech & Genomics funds
  • Median 0.47%

15 of the 17 Biotech & Genomics funds charge less.

ARKG costs $75.00 a year on $10,000. The median Biotech & Genomics fund costs $47.00.

Other funds in Biotech & Genomics

See others